Advertisement
Bavarian Nordic initiates Phase 2 trial
Nordic Life Science
Related Posts
Nanoform has announced the completion and final results of its clinical study. The primary, secondary and optional exploratory objectives of the study were all met. The results show that Nanoform’s CESS technology enabled development of a fast-acting piroxicam immediate release (IR) tablet formulation with more rapid absorption and improved drug…
AstraZeneca and MSD have announced positive results from the Phase III POLO trial. Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Lynparza (olaparib) vs. placebo. The safety and tolerability profile of Lynparza was consistent with previous trials. POLO is a randomized, double-blinded, placebo-controlled trial exploring the efficacy…
NeuroVive Pharmaceutical and Yungjin Pharm announces that the phase I clinical study in Korea within the companies’ joint project KL1333, an investigational treatment for genetic mitochondrial disorders, including MELAS (Mitochondrial Myopathy, Encephalopahty, Lactic Acidosis and Stroke-like episodes), is proceeding according to plan. The first part of the study has been…
Galecto’s oral small molecule galectin-3 inhibitor, GB1211, was well tolerated in pre-clinical and Phase 1 studies and is ready to start a Phase 2a clinical study to treat liver fibrosis in Non-Alcoholic SteatoHepatitis (NASH). GB1211 has been shown to be effective in several pre-clinical fibrosis models, without any signs of…